ICCCHIGH SIGNALFINANCIAL10-K

ICCC achieved a dramatic operational turnaround with revenue jumping 51.6% to $26.5M and swinging from a $1.6M operating loss to $1.6M operating profit.

This represents a significant inflection point for the company, demonstrating that management's strategic focus is generating substantial top-line growth while achieving operational leverage. The addition of formal cybersecurity governance language suggests the company is maturing its risk management practices alongside its financial performance.

Comparing 2026-03-30 vs 2025-03-28View on EDGAR →
FINANCIAL ANALYSIS

ICCC delivered exceptional financial performance with revenue surging 51.6% to $26.5M and achieving a remarkable $3.2M swing from operating loss to operating profit of $1.6M. The company generated strong cash flow improvement (operating cash flow up 592% to $2.5M) while investing heavily in growth with capex increasing 169% to $1.3M and inventory growing 30% to support demand. Despite the operational turnaround, net income remained negative at -$1.0M due to higher interest expense, though this improved significantly from the prior year's -$2.2M loss.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+591.6%
$358K$2.5M

Operating cash flow surged 591.6% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+200.6%
-$1.6M$1.6M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
+168.5%
$466K$1.3M

Capital expenditure jumped 168.5% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
+51.8%
-$2.2M-$1.0M

Net income grew 51.8% — bottom-line growth signals improving overall business health.

Revenue
P&L
+51.6%
$17.5M$26.5M

Strong top-line growth of 51.6% — accelerating demand or successful expansion into new markets.

Gross Profit
P&L
+44.1%
$7.9M$11.4M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Interest Expense
P&L
+36.5%
$349K$476K

Interest expense surged 36.5% — significant debt increase or rising rates materially impacting earnings.

Inventory
Balance Sheet
+30.3%
$7.1M$9.3M

Inventory surged 30.3% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

R&D Expense
P&L
-22%
$3.9M$3.0M

R&D spending cut 22% — could signal cost discipline or concerning reduction in innovation investment.

Current Assets
Balance Sheet
+12.6%
$15.0M$16.9M

Current assets grew 12.6% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-28
ADDED
iccc20251231_10k.htm 0000811641 ImmuCell Corporation false --12-31 FY 2025 true true true false Our Board of Directors has overall oversight responsibility with respect to our approach to risk management, including risks relating to cybersecurity.
Although the Board of Directors has the ultimate responsibility for risk oversight, our management team, including our President and CEO, has operational responsibility for cybersecurity matters, including the day-to-day management of our cybersecurity risks, and oversees processes for the prevention, detection, mitigation and remediation of any cybersecurity incidents.
While our management team does not have cybersecurity expertise, we coordinate with expert consultants to assess and manage risks.
Our Board of Directors reviews cybersecurity threats and risk controls based on information provided by management and outside consultants.
Our Board of Directors has overall oversight responsibility with respect to our approach to risk management, including risks relating to cybersecurity.
+7 more — sign up free →
REMOVED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
1 ImmuCell Corporation OUTLINE TO ITEM 1 BUSINESS: - Summary - Production Capacity Increase and Product Contamination - Animal Health Products - Sales and Markets - Product Development - Competition - Intellectual Property - Government Regulation - Employees - Public Information Summary ImmuCell Corporation was founded in 1982 and completed an initial public offering of common stock in 1987.
After achieving approval from the Center for Veterinary Biologics, U.S.
Department of Agriculture (USDA) to sell First Defense in 1991, we focused most of our efforts during the 1990 s on attempting to develop human product applications of the underlying milk protein purification technology.
Beginning in 1999, we re-focused our business strategy on the First Defense product line.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →